EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Missense Mutations in the KAT Domain of CREBBP Gene in Patients with Follicular Lymphoma: Implications for Differential Diagnosis and Prognosis

Anna Smolianinova iD, Ivan Bolshakov, Yulia Sidorova iD, Alla Kovrigina iD, Tatiana Obukhova iD, Nelli Gabeeva, Eduard Gemdzhian iD, Elena Nikulina, Bella Biderman iD, Nataliya Severina, Nataliya Risinskaya iD, Andrey Sudarikov iD und 2 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26146913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anna Smolianinova und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Medical Research Center for Hematology, 125167 Moscow, Russia. Hauptthemen laut MEDLINE: CREB-Binding Protein, Lymphoma, Follicular, Mutation, Missense. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular lymphoma (FL) is one of the most common types of non-Hodgkin’s lymphomas. The tumor is characterized by a wide range of clinical manifestations, ranging from indolent forms to early transformation and progression with a poor prognosis. The search for clinically significant genetic changes is essential for personalized risk assessment and treatment selection. The CREBBP gene is frequently mutated in this type of lymphoma, with changes occurring at the level of the earliest tumor precursor cells. However, the prognostic and diagnostic significance of the CREBBP gene mutation status in FL has not been fully established. In this study, we analyzed sequencing data of exons 22–30 of the CREBBP gene in 86 samples from patients with different grades of FL (1–3B), including those in the 3A–3B subgroup without the t(14;18) translocation. We also investigated the prognostic significance of CREBBP gene mutations in relation to the treatment options, namely high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HDCT/auto-HSCT) and conventional chemotherapy programs (CCT). It was found that FL patients with a single missense mutation in the KAT domain of the CREBBP gene experienced an extremely low number of early adverse events related to lymphoma and had better long-term survival rates, regardless of treatment option. In contrast, when comparing patients with FL without a missense mutation in the KAT domain or those with multiple mutations in the CREBBP gene, overall and progression free survival were worse, and early progression and histological transformation were more common. Compared to standard therapy, patients who underwent HDCT/auto-HSCT in the FL 1–3B (14;18)-positive group without a single missense mutation in the KAT domain had better survival rates and lower rates of transformation and early progression. In addition, among patients with FL 3A–3B (14;18)-negative, we found that there were no cases of a missense mutation in the KAT domain of the CREBBP gene. This suggests that a single missense mutation in the CREBBP gene may be a feature that discriminates 14;18-positive FL with a favorable prognosis from a high-risk disease. FL 3A–3B (14;18)-negative may represent a distinct variant with different biology and underlying mechanisms of development compared to classical FL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CREB-Binding ProteinLymphoma, FollicularMutation, MissenseHumansMaleFemaleMiddle AgedPrognosisAdultAgedHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

CREBBPNGSchemotherapyfollicular lymphoma

Substanzen

CREB-Binding ProteinCREBBP protein, human

Autor:innen und Institutionen

  • National Medical Research Center for Hematology, 125167 Moscow, Russia.

ORCID-Profile: Anna Smolianinova, Yulia Sidorova, Alla Kovrigina, Tatiana Obukhova, Eduard Gemdzhian, Bella Biderman, Nataliya Risinskaya, Andrey Sudarikov

Zitieren

APA

Smolianinova, A., Bolshakov, I., Sidorova, Y., Kovrigina, A., Obukhova, T., Gabeeva, N., Gemdzhian, E., Nikulina, E., Biderman, B., Severina, N., Risinskaya, N., Sudarikov, A., Zvonkov, E., & Parovichnikova, E. (2025). Missense Mutations in the KAT Domain of CREBBP Gene in Patients with Follicular Lymphoma: Implications for Differential Diagnosis and Prognosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146913

Vancouver

Smolianinova A, Bolshakov I, Sidorova Y, Kovrigina A, Obukhova T, Gabeeva N, et al. Missense Mutations in the KAT Domain of CREBBP Gene in Patients with Follicular Lymphoma: Implications for Differential Diagnosis and Prognosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146913

BibTeX
@article{Smolianinova2025,
  author = {Smolianinova, Anna and Bolshakov, Ivan and Sidorova, Yulia and Kovrigina, Alla and Obukhova, Tatiana and Gabeeva, Nelli and Gemdzhian, Eduard and Nikulina, Elena and Biderman, Bella and Severina, Nataliya and Risinskaya, Nataliya and Sudarikov, Andrey and Zvonkov, Eugeniy and Parovichnikova, Elena},
  title = {Missense Mutations in the KAT Domain of CREBBP Gene in Patients with Follicular Lymphoma: Implications for Differential Diagnosis and Prognosis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26146913}
}
Kostenlos starten →